Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial

Jeremy Pettus, Dominic Reeds, Tricia S. Cavaiola, Schafer Boeder, Michelle Levin, Garry Tobin, Edda Cava, Dung Thai, Jim Shi, Hai Yan, Edgar Bautista, John McMillan, Roger H Unger, Robert R. Henry, Samuel Klein

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70-mg dose of REMD-477 (half-life 7-10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD-477 than with placebo (P =.02). Continuous glucose monitoring during post-treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P <.001), percent time-in-target-range (70-180 mg/dL) was ~25% greater (~3.5 h/d) (P =.001), and percent time-in-hyperglycaemic-range (> 180 mg/dL) was ~40% lower (~4 h/d) (P =.001) in the REMD-477 group than in the placebo group, without a difference in percent time-in-hypoglycaemic-range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1302-1305
Number of pages4
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number5
DOIs
StatePublished - May 2018

Keywords

  • diabetes
  • glucose homeostasis
  • glycaemic control, insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this